Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
MRKR Stock Chart & Stats
$1.31
-$0.17(-5.70%)
At close: 4:00 PM EST
$1.31
-$0.17(-5.70%)
Day’s Range― - ―
52-Week Range$0.81 - $4.07
Previous CloseN/A
Volume39.59K
Average Volume (3M)137.12K
Market Cap
$21.84M
Enterprise Value-$16.07T
Total Cash (Recent Filing)$16.07T
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 20, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding16,673,126
10 Day Avg. Volume121,728
30 Day Avg. Volume137,122
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)<0.01
Price to Sales (P/S)6.43
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-735.66K
Enterprise Value/Revenue-4.53M
Enterprise Value/Gross Profit3.30M
Enterprise Value/Ebitda1.97M
Forecast
1Y Price Target
$9.00Price Target Upside587.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$2.68M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPublished Phase 1/2 and partner trial data showed favorable safety, in vivo expansion, and signs of tumor control for MAR-T therapies, supporting further development in both hematologic and solid tumors.
Manufacturing And Patient AccessPlanned manufacturing scale-up and progress with the off-the-shelf MT-401 program aim to shorten vein-to-vein delivery and simplify production, which could improve patient access compared with existing cell therapies.
Regulatory PathwayAn FDA meeting could clarify pivotal-study design and acceptance of an overall response rate endpoint, potentially reducing regulatory hurdles for MT-601's transition to a pivotal-stage program.
Bears Say
Development And Commercial RisksClinical development uncertainty, competition from other immunotherapies, and reimbursement and capital-market challenges create substantial execution risks that could hinder value realization.
Liquidity And RunwayLimited cash on hand could constrain the financial runway and pressure near-term operations and clinical development plans.
Marker Therapeutics News
MRKR FAQ
What was Marker Therapeutics Inc’s price range in the past 12 months?
Marker Therapeutics Inc lowest stock price was $0.81 and its highest was $4.07 in the past 12 months.
What is Marker Therapeutics Inc’s market cap?
Marker Therapeutics Inc’s market cap is $21.84M.
When is Marker Therapeutics Inc’s upcoming earnings report date?
Marker Therapeutics Inc’s upcoming earnings report date is May 20, 2026 which is in 56 days.
How were Marker Therapeutics Inc’s earnings last quarter?
Marker Therapeutics Inc released its earnings results on Mar 18, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.191 by $0.091.
Is Marker Therapeutics Inc overvalued?
According to Wall Street analysts Marker Therapeutics Inc’s price is currently Undervalued.
Does Marker Therapeutics Inc pay dividends?
Marker Therapeutics Inc does not currently pay dividends.
What is Marker Therapeutics Inc’s EPS estimate?
Marker Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Marker Therapeutics Inc have?
Marker Therapeutics Inc has 16,673,126 shares outstanding.
What happened to Marker Therapeutics Inc’s price movement after its last earnings report?
Marker Therapeutics Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.191. Following the earnings report the stock price went down -1.493%.
Which hedge fund is a major shareholder of Marker Therapeutics Inc?
Currently, no hedge funds are holding shares in MRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
MRKR Stock 12 Month Forecast
Average Price Target
$9.00
▲(587.02% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
18.09%
Insiders
2.09% Mutual Funds
15.56% Other Institutional Investors
62.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---